Tango Therapeutics Inc (TNGX) said before open Wednesday that it lost $0.28 per share in quarter two 2022. The company reported $5.8 million in revenue
In the same quarter a year ago, the company lost $0.09 per share on revenue of $18.2 million.
The stock is up 19.46% to $4.85 after the report.
Despite Tango Therapeutics Inc reporting a decline in revenues, earnings increased signaling a rise in profit margins.
Wall Street Analysts had an average rating of Strong Buy on the stock prior to the report.
Trading in the five days leading up to the report earned Tango Therapeutics Inc a Bearish Sentiment Rank from InvestorsObserver.
Tango Therapeutics Inc has performed poorly during the past few months, garnering a low Long-Term Technical Rank by InvestorsObserver of 3, putting Tango Therapeutics Inc in the bottom 25% of stocks. The firm was recently trading at a 52-week low of $3.71 on June 14, 2022 and set a 52-week high on September 17, 2021 at $18.84.
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer.
News Home
Tango Therapeutics Inc Up 19.46% To $4.85 After Earnings
Mentioned in this article
